GVR Report cover Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Report

Neglected Tropical Diseases Diagnosis Market Size, Share & Trends Analysis Report By Disease (Dengue, Chikungunya), By Diagnostic Method (Conventional, Molecular/Modern), By Service Type, By End-use, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-2-68038-319-5
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Range: 2017 - 2020
  • Industry: Healthcare

Report Overview

The global neglected tropical diseases (NTD) diagnosis market size was valued at USD 6.09 billion in 2021 and is expected to expand at a CAGR of 4.4% during the forecast period. Growing awareness of NTDs and an increasing number of initiatives undertaken by the government are anticipated to fuel the market growth. For instance, the inclusion of NTDs in the Sustainable Development Goals (SDG), a United Nations Development Program, as a global target is anticipated to fuel market growth. Furthermore, various initiatives being undertaken by WHO, such as road map 2030 for the elimination of NTDs, are expected to drive market growth during the forecast period.

U.K. neglected tropical disease diagnosis market size, by service type, 2020- 2030 (USD Million)

In the wake of the COVID-19 pandemic, the neglected tropical disease (NTD) diagnosis witnessed a significant decline. WHO launched the Global Program to Eliminate Lymphatic Filariasis (GPELF) in 2000, which aims to stop the spread of the infection and relieve the pain of those who have already been afflicted. However, according to the pulse survey conducted by WHO, as of early 2021, the neglected tropical disease program has faced disruptions in 44% of countries. Moreover, the high risk of transmission of SARS-CoV-2 infection has affected the public health approaches for NTDs. In countries with low health budgets, funds being shifted to tackle other diseases, and a shortage of funding from international partners and the foreign government has significantly impacted the growth of the market.

The NTD program has expanded its support to 31 countries in Asia, Latin America, and Africa. Besides, it has provided more than 2.6 billion treatments and leveraged more than USD 22.3 billion in donated medicines. Government organizations such as CDC and WHO collaborate with counties to improve existing public health services for NTDs. Moreover, in January 2021, the WHO introduced its roadmap for NTDs for the period 2021 to 2030. It is aimed to increase the prevention and control of neglected tropical diseases worldwide. Such initiatives undertaken by the government bodies are anticipated to drive the market growth during the forecast period.

Globally, several organizations initiated multiple programs, which contribute to rising in the awareness of NTDs, including the Global NTD Program by the Centers for Disease Control and Prevention, Global NTD Programs by the World Health Organization, NTD Program by the United States Agency for International Development, the United States Global Health Initiative. The primary focus of all these programs is on controlling or eliminating NTDs. Similarly, the London Declaration was initiated to sustain, expand, and extend different programs to support & control guinea worm disease, leprosy, lymphatic filariasis, sleeping sickness, trachoma, schistosomiasis, and Chagas disease by 2020.

The increasing burden of NTDs is considered to be a major factor fueling the growth of the overall market during the forecast period. According to WHO estimates, more than 1.7 billion individuals, about one-fifth of the world’s population, mostly in lower-income and developing countries-required interventions for at least one NTD every year. Around 40% of the African region was affected by NTDs. These diseases are more prevalent among the poor population living in tropical environments and difficult-to-access areas. Countries such as Brazil, Yemen, India, Bangladesh, China, and some countries in Central & East Africa contribute the majority of NTD cases globally.

Disease Insights

Based on disease, soil-transmitted helminthiases dominated the market in 2021, owing to the increasing prevalence and high adoption of diagnostic tests. Moreover, the low false-positive rate of molecular diagnostics provides a competitive advantage over conventional and rapid tests. Furthermore, according to the WHO, as of January 2022, more than 1.5 billion people are infected with soil-transmitted helminth infections worldwide. The Kato-Katz technique is the WHO gold standard that is widely used to diagnose the intensity of STHs. Besides, neglected tropical diseases such as dengue, chikungunya, lymphatic filariasis, foodborne trematode infections, and others also held a significant share of the global market.

The dracunculiasis segment is estimated to exhibit the fastest CAGR of 5.5% during the forecast period. It is a crippling parasitic infection on the verge of extinction, with 27 human cases registered in 2020. Out of these, 12 human cases of Guinea worm illness (dracunculiasis) were reported in Chad in 2020—a 75% decrease from 48 in 2019. In Ethiopia, 11 such cases have been documented, with one each in Angola, Cameroon South, Sudan, and Mali. The extension of disease and growing awareness among the population, and higher costs of the test may also contribute to the segment’s growth in terms of revenue.

Diagnostics method Insights

The molecular/modern diagnostic segment dominated the market in 2021 with a revenue share of around 50.07%, which can be attributed to high usage rates. Moreover, the segment is anticipated to experience the fastest growth rate during the forecast period. An increase in R&D for molecular diagnostic techniques coupled with a rise in demand for point-of-care products is expected to boost the market expansion at a CAGR of 5.0% by 2030.

Factors taken into consideration while opting for various diagnostic methods include specificity, sensitivity, cost-effectiveness, and the availability of skilled personnel. Conventional diagnostic methods are based on microscopic & macroscopic identification of pathogens through gram stain, pathogen culturing, biochemical methods, and serology tests.

Relatively higher availability of conventional methods, compared to modern techniques, across many labs and clinics is a key factor that has enabled this segment to dominate in the market. However, these tests exhibit certain limitations relating to speed, timeline, and accuracy. Furthermore, rapid technological advances are compelling end-users to opt for molecular/modern methods over conventional methods.

Service Type Insights

Centralized service was the largest segment in terms of market share in 2021, owing to the high procedure volume and the wide presence of ancillary support in terms of infrastructure and human resources. However, the PoC segment is likely to be the fastest-growing segment during the forecast period. Rising demand for bedside patient care due to the booming home healthcare market, technological advancements, and increasing market penetration are among the major factors driving the segment growth.

Furthermore, POC services provide quick results, allowing immediate diagnosis and better patient outcomes. Moreover, in 2017, the U.S. FDA approved the first POC test, “Chagas Detect Plus Rapid Test Kit” a 510K clearance. This POCT for Chagas disease has been developed by InBios International. Such achievements are anticipated to impact the growth of this segment positively throughout the forecast period.

End-use Insights

The clinical laboratory segment held the largest market share in terms of revenue in 2021, owing to high market penetration & procedure volumes and many laboratories in emerging & underdeveloped markets. Moreover, an increase in the number of initiatives undertaken by the government to provide various services, such as reimbursement for diagnostic tests, is another major factor anticipated to drive the market. However, the home healthcare segment is expected to grow at the fastest growth rate owing to the increasing adoption of point of care testing services. 

Global neglected tropical diseases diagnosis market share, by end-use, 2021 (%)

The hospitals/clinics segment held the second-largest market share in 2021. Public health laboratories serve an important role in performing high-quality testing for NTDs and associated antimicrobial resistance. Moreover, the growing disease burden and rising healthcare expenditure may boost segment growth. In addition, the WHO guidelines for the management and eradication of diseases can be achieved through timely treatment and testing by hospitals & clinics.

Regional Insights

NTDs have become endemic in over 150 countries and have affected people globally. Asia Pacific held a 31.35% share of the neglected tropical diseases diagnosis market in 2021. This is due to the high disease burden of NTDs, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, and a rise in customer awareness about the use of PCR tests in diagnosing NTDs.

Latin America is expected to show the fastest CAGR of 5.3% during the projected period due to increased IVD product penetration and the high disease burden of NTDs in developing countries in the region.In addition, an increase in government spending, the presence of skilled healthcare professionals, and a rise in the focus of multinational diagnostic companies on the development of advanced & novel IVD products are among the factors likely to drive market growth in Latin America. However, low awareness about the prevention & treatment of infectious diseases in underdeveloped areas and the lack of favorable reimbursement policies are some of the key factors restraining market growth.

Recently, Argentina proposed reform in its healthcare system, stating that the controlling power of private pavers should be with the government. This may lead to affordable pricing of tests for the common population, leading to an increase in the demand for IVD instruments and reagents.

Neglected Tropical Disease Diagnosis Market Share Insights

Key players are undertaking various strategic initiatives to increase their share in the market. New product development, collaborations, and partnerships are some such endeavors. For instance, in March 2021, EUROIMMUN launched the EUROPatternTM Microscope Live (EPML) compact immunofluorescence microscope used to detect antibodies in the sample and enhance the quality of indirect immunofluorescence testing.

Some of the key players in the global neglected tropical disease diagnosis market include:

  • F. Hoffmann-La Roche Ltd

  • Abbott

  • Thermo Fisher Scientific Inc.

  • ZeptoMetrix

  • InBios International, Inc.

  • Genome Diagnostics Pvt. Ltd.

  • Omega Diagnostics Group PLC

  • Coris BioConcept

  • DiaSys Diagnostic Systems GmbH

  • Oscar Medicare Pvt Ltd.


Neglected Tropical Disease Diagnosis Market Report Scope

Report Attribute


Market size value in 2022

USD 6.32 billion

Revenue forecast in 2030

USD 8.97 billion

Growth rate

CAGR of 4.4% from 2022 to 2030

Base year for estimation


Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Disease, diagnostic method, service type, end-use

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; China; India; Indonesia; Malaysia; Brazil; Colombia; Venezuela; Nigeria

Key companies profiled

F. Hoffmann-La Roche Ltd; Abbott; Thermo Fisher Scientific Inc.; ZeptoMetrix; InBios International, Inc.; Genome Diagnostics Pvt. Ltd.; Omega Diagnostics Group PLC; Coris BioConcept; DiaSys Diagnostic Systems GmbH; Oscar Medicare Pvt Ltd.

Customization scope

Free report customization (equivalent to up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2017 to 2030. For this report, Grand View Research has segmented the neglected tropical disease diagnosis market based on disease, diagnostic method, service type, end-use, and regions. 

  • Disease Outlook (Revenue, USD Million, 2017 - 2030)

    • Dengue

    • Chikungunya

    • Rabies

    • Leprosy

    • Buruli Ulcer

    • Yaws

    • Lymphatic Filariasis

    • Taeniasis/Cysticercosis

    • Foodborne Trematodiases

    • Echinococcosis

    • Chagas Disease (American Trypanosomiasis)

    • Dracunculiasis

    • African Trypanosomiasis

    • Soil-transmitted Helminth Infections

    • Onchocerciasis

    • Schistosomiasis

    • Scabies and Other Ectoparasites

    • Snakebite Envenoming

    • Leishmaniasis

  • Diagnostic Method Outlook (Revenue, USD Million, 2017 - 2030)

    • Conventional Method

    • Molecular/Modern Method

  • Service Type Outlook (Revenue, USD Million, 2017 - 2030)

    • Centralized Service

    • POC Service

  • End-Use Outlook (Revenue, USD Million, 2017 - 2030)

    • Clinical Labs

    • Hospitals /Clinics

    • Home Healthcare

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • UK

    • Asia Pacific

      • China

      • India

      • Indonesia

      • Malaysia

    • Latin America

      • Brazil

      • Colombia

      • Venezuela

    • Middle East and Africa (MEA)

      • Nigeria

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon